Tolremo Therapeutics

Executive Summary

Tolremo Therapeutics is a Swiss biotech company pioneering a novel approach to combat non-genetic cancer drug resistance. Founded in 2017 and headquartered in Basel, the company aims to prevent resistance from emerging in the first place by targeting the earliest cellular defense mechanisms that enable cancer cells to survive targeted therapies. Unlike traditional approaches that tackle resistance after it develops, Tolremo's platform addresses a universal challenge across multiple targeted therapies, potentially extending their durability and improving patient outcomes. The company's small-molecule pipeline is designed to disrupt adaptive resistance pathways, offering a complementary strategy to existing and future oncology treatments. While Tolremo is still in the preclinical to early clinical stage, its scientific premise addresses a critical unmet need in oncology. The company may have upcoming catalysts including initiation of Phase I trials, strategic partnerships, or financing rounds to advance its lead program. Given the early stage and lack of disclosed pipeline details, the conviction score is moderate, reflecting the high potential of the approach balanced against development risks.

Upcoming Catalysts (preview)

• Q2 2026Initiation of First-in-Human Phase I Trial for Lead Asset60% success
• Q3 2026Series B Financing or Strategic Partnership Announcement70% success
• Q4 2026Presentation of Preclinical Proof-of-Concept Data at Major Conference80% success